22nd Century Group Inc (NASDAQ:XXII)
| 1.10 Delayed Data As of Jan 27 |  -0.05 / -4.35%Today’s Change | 0.82 Today|||52-Week Range 2.71 | +19.50% Year-to-Date |
Latest XXII News | Press Releases
No recent news for 22nd Century Group Inc.
Today’s Trading
| Previous close | 1.15 |
| Today’s open | 1.14 |
| Day’s range | 1.10 - 1.14 |
| Volume | 59,317 |
| Average volume (3 months) | 1,445,917 |
| Market cap | $258.4M |
Data as of 4:00pm ET, 01/27/2023
Growth & Valuation
| Earnings growth (last year) | -48.62% |
| Earnings growth (this year) | -16.04% |
| Earnings growth (next 5 years) | +30.00% |
| Revenue growth (last year) | +10.09% |
| P/E ratio | NM |
| Price/Sales | 15.60 |
| Price/Book | 2.96 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| XOMAXOMA Corp | -0.14 | -0.66% |
| LCTXLineage Cell Therape... | -0.01 | -0.71% |
| RCELAVITA Medical Inc | 0.00 | 0.00% |
| ---- |
Data as of 4:00pm ET, 01/27/2023
Financials
| Next reporting date | March 8, 2023 |
| EPS forecast (this quarter) | -$0.06 |
| Annual revenue (last year) | $30.9M |
| Annual profit (last year) | -$32.6M |
| Net profit margin | -105.37% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters Buffalo, New York |
Forecasts
